Transaction DateRecipientSharesTypePriceValue
22nd February 2021Jason Ehrlich1,611Open or private sale$125.97$202,940.73
22nd February 2021Jason Ehrlich2,150Open or private sale$124.92$268,573.92
22nd February 2021Jason Ehrlich413Open or private sale$129.18$53,349.61
22nd February 2021Jason Ehrlich1,827Open or private sale$127.34$232,650.36
22nd February 2021Jason Ehrlich262Open or private sale$122.00$31,963.66
22nd February 2021Jason Ehrlich687Open or private sale$123.56$84,888.61
22nd February 2021Jason Ehrlich6,950Exercise of derivative$10.29$71,515.50
17th February 2021Bros. Advisors Lp Baker5,792,538Open or private purchase$16.00$92,680,608.00
17th February 2021Bros. Advisors Lp Baker457,462Open or private purchase$16.00$7,319,392.00
20th January 2021Jason Ehrlich2,061Open or private sale$163.10$336,139.21
Kodiak Sciences
Kodiak Sciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.

Ticker: KOD
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1468748
Employees: 39
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags